Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that its board of directors will hold a meeting on October 27, 2025, to consider and approve the company’s quarterly results for the nine months ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming quarters.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$97.80 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the development, production, and marketing of a wide range of pharmaceutical products. The company focuses on providing innovative healthcare solutions and has a significant presence in the pharmaceutical industry.
Average Trading Volume: 5,431,739
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$494.1B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.